Following the groundbreaking commitments GlaxoSmithKline (GSK) made to improve access to medicines for neglected diseases in least developed countries, Andrew Witty, CEO of GSK, revisited Kenya and Uganda to see, first-hand, the impact of established community programmes and explore what more can be done.
All Comments